Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$15.5 million.

  • CytomX Therapeutics' Cash from Operations rose 2499.4% to -$15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.3 million, marking a year-over-year increase of 1816.14%. This contributed to the annual value of -$86.2 million for FY2024, which is 5388.77% down from last year.
  • Latest data reveals that CytomX Therapeutics reported Cash from Operations of -$15.5 million as of Q3 2025, which was up 2499.4% from -$15.8 million recorded in Q2 2025.
  • CytomX Therapeutics' Cash from Operations' 5-year high stood at $9.3 million during Q1 2023, with a 5-year trough of -$41.3 million in Q1 2022.
  • In the last 5 years, CytomX Therapeutics' Cash from Operations had a median value of -$22.0 million in 2023 and averaged -$22.3 million.
  • Examining YoY changes over the last 5 years, CytomX Therapeutics' Cash from Operations showed a top increase of 12262.97% in 2023 and a maximum decrease of 147666.91% in 2023.
  • Quarter analysis of 5 years shows CytomX Therapeutics' Cash from Operations stood at -$31.2 million in 2021, then soared by 95.53% to -$1.4 million in 2022, then tumbled by 1476.67% to -$22.0 million in 2023, then grew by 9.36% to -$19.9 million in 2024, then rose by 21.9% to -$15.5 million in 2025.
  • Its Cash from Operations stands at -$15.5 million for Q3 2025, versus -$15.8 million for Q2 2025 and -$21.0 million for Q1 2025.